MEF2D and acute lymphoblastic leukemia: MEF2D-rearranged ALL has a distinct immunophenotype (CD10−, CD38+), and this rearrangement results in increased HDAC9 expression and sensitivity to histone deacetylase inhibitors [49,50,51].